These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11416781)

  • 1. Postmenopausal hormone use, screening, and breast cancer: characterization and control of a bias.
    Joffe MM; Byrne C; Colditz GA
    Epidemiology; 2001 Jul; 12(4):429-38. PubMed ID: 11416781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Digital versus screen-film mammography: impact of mammographic density and hormone therapy on breast cancer detection.
    Chiarelli AM; Prummel MV; Muradali D; Shumak RS; Majpruz V; Brown P; Jiang H; Done SJ; Yaffe MJ
    Breast Cancer Res Treat; 2015 Nov; 154(2):377-87. PubMed ID: 26518019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does hormone replacement therapy increase the frequency of breast atypical hyperplasia in postmenopausal women? Results from the Bouches du Rhone district screening campaign.
    Gayet A; Estève J; Séradour B; Piana L; Jacquemier J
    Eur J Cancer; 2003 Aug; 39(12):1738-45. PubMed ID: 12888369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammographic screening and risk factors for breast cancer.
    Cook NR; Rosner BA; Hankinson SE; Colditz GA
    Am J Epidemiol; 2009 Dec; 170(11):1422-32. PubMed ID: 19875646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population.
    Kerlikowske K; Miglioretti DL; Buist DS; Walker R; Carney PA;
    J Natl Cancer Inst; 2007 Sep; 99(17):1335-9. PubMed ID: 17698950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mammographic density, response to hormones, and breast cancer risk.
    Boyd NF; Melnichouk O; Martin LJ; Hislop G; Chiarelli AM; Yaffe MJ; Minkin S
    J Clin Oncol; 2011 Aug; 29(22):2985-92. PubMed ID: 21709206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast density changes associated with hormone replacement therapy in postmenopausal women. Effects on the specifity and sensitivity of mamographic screening.
    Howard JM
    Eur J Gynaecol Oncol; 2006; 27(1):104; author reply 104. PubMed ID: 16550985
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales.
    Waller M; Moss S; Watson J; Møller H
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2257-61. PubMed ID: 18006913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?
    Sterns EE; Zee B
    Breast Cancer Res Treat; 2000 Jan; 59(2):125-32. PubMed ID: 10817347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor and mammographic density in postmenopausal Norwegian women.
    Bremnes Y; Ursin G; Bjurstam N; Rinaldi S; Kaaks R; Gram IT
    Cancer Epidemiol Biomarkers Prev; 2007 Jan; 16(1):57-62. PubMed ID: 17220332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of estrogen receptor alpha and progesterone receptor polymorphisms on the effects of hormone therapy on mammographic density.
    van Duijnhoven FJ; Peeters PH; Warren RM; Bingham SA; Uitterlinden AG; van Noord PA; Monninkhof EM; Grobbee DE; van Gils CH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):462-7. PubMed ID: 16537702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammographic density as a surrogate marker for the effects of hormone therapy on risk of breast cancer.
    Boyd NF; Martin LJ; Li Q; Sun L; Chiarelli AM; Hislop G; Yaffe MJ; Minkin S
    Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):961-6. PubMed ID: 16702377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.
    Ravdin PM
    Breast Dis; 2008-2009; 30():3-8. PubMed ID: 19850989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study.
    Zahl PH; Gøtzsche PC; Mæhlen J
    Lancet Oncol; 2011 Nov; 12(12):1118-24. PubMed ID: 21996169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimates of overdiagnosis of invasive breast cancer associated with screening mammography.
    Morrell S; Barratt A; Irwig L; Howard K; Biesheuvel C; Armstrong B
    Cancer Causes Control; 2010 Feb; 21(2):275-82. PubMed ID: 19894130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone therapy use and breast cancer incidence by histological subtypes in Sweden and Norway.
    Suhrke P; Mæhlen J; Zahl PH
    Breast J; 2012; 18(6):549-56. PubMed ID: 23002918
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.